Coverage dated November 29, 2021 to December 1, 2021
UK approves GSK COVID drug, appears effective against Omicron
Headline from MedicalXpress, on the newest of 2 developments
British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe COVID-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant.
MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Regeneron says its antibody treatment 'may be' less effective against omicron
Headline from The Hill ·
Newest
UK approves GSK COVID drug, appears effective against Omicron
US biotech firm Regeneron said Tuesday that its synthetic antibody treatment for Covid-19 may be less effective against the new variant, and it plans to conduct tests to determine by how much.
A pharmaceutical company announced on Thursday its research indicates an investigational monoclonal antibody it is developing is effective against mutations of the omicron variant of COVID-19.
The treatment, co-developed by GSK, gained approval from the U.K’s medicines regulator after a clinical trial showed a single dose slashed the risk of hospitalisation and death by 79% in high-risk adults with symptomatic infection.
GlaxoSmithKline has said its COVID-19 therapy appeared to work against the new omicron variant. Greece has imposed a vaccine mandate for over-60s. Follow DW for the latest.
British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe COVID-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant.
